 AcelRx continues to be an abysmal investment as the companys flagship product DSUVIA has struggled to gain traction in the middle of COVID-19 headwinds. The lack of DoD orders are hurting the companys quarterly earnings. Consequently, the share price has been crushed and the companys market. 